Abstract:Patients, life science industry and regulatory authorities are united in their goal to reduce the disease burden of patients by closing remaining unmet needs. Patients have, however, not always been systematically and consistently involved in the drug development process. Recognizing this gap, regulatory bodies worldwide have initiated patient-focused drug development (PFDD) initiatives to foster a more systematic involvement of patients in the drug development process and to ensure that outcomes measured in clinical trials are truly relevant to patients and represent significant improvements to their quality of life. As a source of real-world evidence (RWE), social media has been consistently shown to capture the first-hand, spontaneous and unfiltered disease and treatment experience of patients and is acknowledged as a valid method for generating patient experience data by the Food and Drug Administration (FDA). While social media listening (SML) methods are increasingly applied to many diseases and use cases, a significant piece of uncertainty remains on how evidence derived from social media can be used in the drug development process and how it can impact regulatory decision making, including legal and ethical aspects. In this policy paper, we review the perspectives of three key stakeholder groups on the role of SML in drug development, namely patients, life science companies and regulators. We also carry out a systematic review of current practices and use cases for SML and, in particular, highlight benefits and drawbacks for the use of SML as a way to identify unmet needs of patients. While we find that the stakeholders are strongly aligned regarding the potential of social media for PFDD, we identify key areas in which regulatory guidance is needed to reduce uncertainty regarding the impact of SML as a source of patient experience data that has impact on regulatory decision making.

Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases

Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes

Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators

Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility Assessment

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

Real-World Evidence: A Primer

On the use of RWD in support of regulatory submission in drug development

Expert survey on real‐world data utilization and real‐world evidence generation for regulatory decision‐making in drug lifecycle in Korea

Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals

Leveraging Real-World Data in Safety Signal Assessment

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?

A New Era in Pharmacovigilance: Toward Real‐World Data and Digital Monitoring

Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan

Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment